Inclusion Criteria:
  -  Subject's parent or legal guardian has provided written informed consent/HIPAA authorization
  -  Subject has previously completed at a participating US study site VBP15-LTE up to and including the Month 24 assessments, OR VBP15-004 up to and including the Week 48 assessments, within 30 days prior to participation in the VBP15-EAP
  -  Subject and parent/guardian are willing and able to comply with recommended study drug administration plan, and standard of care follow-up and monitoring as recommended by their Treating Physician
Exclusion Criteria:
  -  Subject had a serious or severe adverse event in study VBP15-LTE or VBP15-004 that, in the opinion of the Treating Physician and Sponsor, was probably or definitely related to vamorolone use and precludes safe use of vamorolone for the subject in this expanded access program
  -  Subject and/or parent/guardian are unable and/or unwilling to comply with regular medical care and follow-up as recommended by their Treating Physician throughout participation in the VBP15-EAP